Examples include trastuzumab (anti-HER2/neu) in combination with paclitaxel in breast cancer [45], rituximab (anti-CD20) in combination with cyclophosphamide/doxorubicin/vincristine/dexamethasone in non-Hodgkin's lymphoma [46] or cetuximab (anti-EGFR) in combination with irinotecan in colon cancer [47]. This evidence concerns the gene KRT20 and breast carcinoma.